© Reuters. FILE PHOTO: GSK (GlaxoSmithKline) logo is seen in this illustration, August 10, 2022. REUTERS/Dado Ruvic/Illustration/File photo
(Reuters) – Britain’s drugs regulator on Monday approved GSK’s drug, Jemperli, to be used with chemotherapy for cancer of the womb lining as a first line treatment.
Jemperli is now authorised to be used together with chemotherapy to slow the progression of endometrial cancers, increasing life expectancy for patients, the UK’s Medicines and Healthcare products Regulatory Agency said.
